Blackstone Group »

Aeglea Biotherapeutics shares owned by Blackstone Group

Quarter-by-quarter ownership of Aeglea Biotherapeutics (SYRE) shares owned by Blackstone Group from 13F filings

Historical chart of Blackstone Group investment in Aeglea Biotherapeutics

Tip: Access up to 7 years of quarterly data

All positions including Aeglea Biotherapeutics held by Blackstone Group consolidated in one spreadsheet with up to 7 years of data

Download as csvDownload consolidated filings csv Download as ExcelDownload consolidated filings xlsx

Quarterly reported holdings in Aeglea Biotherapeutics by Blackstone Group

Quarter filed Position value Share count Share price at filing
2023-12-31 $430k 20k 21.52

More positions owned by Blackstone Group

Cheniere Energy Partners Com Unit (CQP)
Energy Transfer Com Ut Ltd Ptn (ET)
Corebridge Finl (CRBG)
Gates Indl Corp Ord Shs (GTES)
FirstEnergy (FE)
Chesapeake Energy Corp (CHK)
Cheniere Energy Com New (LNG)
PG&E Corporation (PCG)
MPLX Com Unit Rep Ltd (MPLX)
Targa Res Corp (TRGP)
Enterprise Products Partners (EPD)
Bumble Com Cl A (BMBL)
Spdr S&p 500 Etf Tr Tr Unit Put Option (SPY)
Western Midstream Partners L Com Unit Lp Int (WES)
Plains All Amern Pipeline L Unit Ltd Partn (PAA)

View all positions for Blackstone Group

Top funds holding Aeglea Biotherapeutics

Perceptive Advisors
VR Adviser
Commodore Capital
venBio Select Advisor
Cormorant Asset Management
EcoR1 Capital
Franklin Resources
BVF
Wellington Management Company
Citadel Advisors
BlackRock
Braidwell
Global Endowment Management
Vanguard Group
First Turn Management

View all funds holding Aeglea Biotherapeutics